WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR

WINTON GROUP Ltd decreased its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 58.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 153,491 shares of the company’s stock after selling 214,392 shares during the period. WINTON GROUP Ltd owned about 0.09% of Vir Biotechnology worth $1,564,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of VIR. BlackRock Inc. purchased a new stake in Vir Biotechnology in the second quarter worth about $210,712,000. ARCH Venture Management LLC purchased a new position in Vir Biotechnology during the 2nd quarter valued at about $129,353,521. GSK plc bought a new stake in shares of Vir Biotechnology in the 4th quarter valued at about $51,562,000. State Street Corp raised its holdings in shares of Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock valued at $37,564,000 after purchasing an additional 988,262 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Vir Biotechnology in the 1st quarter worth approximately $24,593,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Stock Up 0.4%

Shares of Vir Biotechnology stock opened at $10.62 on Friday. The firm’s 50 day moving average price is $9.83 and its 200-day moving average price is $9.55. Vir Biotechnology, Inc. has a 52-week low of $4.75 and a 52-week high of $11.94. The company has a market cap of $1.80 billion, a P/E ratio of -5.71 and a beta of 1.63.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, August 5th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.14. The company had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 29.99%. Vir Biotechnology’s revenue for the quarter was up 19582.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.80) earnings per share. As a group, equities research analysts forecast that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VIR shares. HC Wainwright reissued a “buy” rating on shares of Vir Biotechnology in a report on Monday, August 10th. Morgan Stanley set a $25.00 target price on Vir Biotechnology in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Leerink Partners boosted their price target on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing therapies for serious infectious diseases and cancer. The company uses technologies involving antibodies, T cells, small interfering RNA and other immune-based approaches to discover and develop treatments designed to harness or enhance the body’s immune response.

Vir’s development programs have included therapies for hepatitis B, influenza, human immunodeficiency virus and other infectious diseases, as well as oncology applications.